Observational Study of Dydrogesterone in Cycle Regularization

Dydrogesterone in Cycle Regularization in Abnormal Uterine Bleeding - Ovulation Dysfunction (AUB-O) Patients: A Prospective, Observational Study

Dydrogesterone has been widely used worldwide for various gynecological and obstetric indications:

• Dydrogesterone is effective in cycle regulation treatment.
• Dydrogesterone is recognized as none interference to hypothalamus pituitary ovary (HPO) axis in the recommended dosage.
• Dydrogesterone might have non-negative effect on glucose and lipid metabolic.

The current study is designed as a prospective, non-interventional, observational study. Patients with irregular cycle diagnosed as AUB-O will be prescribed dydrogesterone as per physician's clinical practice.

Inclusion Criteria:

• Women aged 16 years or above with menses
• Patient who is suffering from irregular menstrual cycle for at least 3 months and has been diagnosed as AUB-O (irregular cycle is defined as cycle duration < 21days or >35 days)
• Physicians have decided to prescribe dydrogesterone 10mg for cycle regulation treatment, orally taking dydrogesterone 10mg twice daily, from day16 to day 25 of each cycle, being consecutive at least 3 cycles
• Patient who is willing to sign written authorization

Exclusion Criteria:

• Hyperprolactinemia and thyroid dysfunction.
• Patient took cycle regulation treatment including oral contraceptives, sex hormone or glucocorticoid in the past 1 month
• Women with estrogen deficiency related symptom
• Patient who meets the contraindications listed in Chinese label of dydrogesterone
• Pregnant and lactating patients
• Patient who is not suitable for the study according to physician's discretion